Hypertrophic cardiomyopathy

Current Problems in Cardiology

Volumn 36, Issue 11, 2011, Pages 409-453

  Ommen, Steve R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; VERAPAMIL;

ANTICHOLINERGIC SYNDROME; ARTICLE; AUTONOMIC DYSFUNCTION; AUTOSOMAL DOMINANT INHERITANCE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR MAGNETIC RESONANCE; CATHETER ABLATION; DEFIBRILLATOR; DIASTOLIC DYSFUNCTION; DRUG EFFICACY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FATIGUE; GENE MUTATION; GENETIC SCREENING; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART SURGERY; HEART VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; MITRAL VALVE REGURGITATION; MITRAL VALVE REPAIR; NONHUMAN; PATHOPHYSIOLOGY; PATIENT COUNSELING; PHYSICAL EXAMINATION; PREVALENCE; PROGNOSIS; SARCOMERE; SUDDEN DEATH; SURVIVAL RATE; SYMPTOM; UNSPECIFIED SIDE EFFECT; URINE RETENTION;

CARDIOMYOPATHY, HYPERTROPHIC; DEATH, SUDDEN, CARDIAC; DECISION TREES; HUMANS; SARCOMERES;

EID: 80053391987     PISSN: 01462806     EISSN: 15356280     Source Type: Journal    
DOI: 10.1016/j.cpcardiol.2011.06.001     Document Type: Article

References (206)

1. Thierfelder L., Watkins H., MacRae C., et al. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 1994, 77:701-712.
2. Roberts R., Sigwart U. New concepts in hypertrophic cardiomyopathies, Part II. Circulation 2001, 104:2249-2252.
3. Roberts R., Sigwart U. New concepts in hypertrophic cardiomyopathies, Part I. Circulation 2001, 104:2113-2116.
4. Marian A.J. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet 2000, 355:58-60.
5. Marian A.J., Roberts R. Molecular genetics of hypertrophic cardiomyopathy. Annu Rev Med 1995, 46:213-222.
6. Seidman J.G., Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 2001, 104:557-567.
7. Yang Q., Sanbe A., Osinska H., et al. A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy. J Clin Invest 1998, 102:1292-1300.
8. Marian A.J., Yu Q.T., Mann D.L., et al. Expression of a mutation causing hypertrophic cardiomyopathy disrupts sarcomere assembly in adult feline cardiac myocytes. Circ Res 1995, 77:98-106.
9. Crilley J.G., Boehm E.A., Blair E., et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol 2003, 41:1776-1782.
10. Roberts R., Marian A.J. Can an energy-deficient heart grow bigger and stronger?. J Am Coll Cardiol 2003, 41:1783-1785.
11. Bonne G., Carrier L., Richard P., et al. Familial hypertrophic cardiomyopathy: from mutations to functional defects. Circ Res 1998, 83:580-593.
12. Watkins H., Seidman C.E., Seidman J.G., et al. Expression and functional assessment of a truncated cardiac troponin T that causes hypertrophic cardiomyopathy. Evidence for a dominant negative action. J Clin Invest 1996, 98:2456-2461.
13. Nagueh S.F., Kopelen H.A., Lim D.S., et al. Tissue Doppler imaging consistently detects myocardial contraction and relaxation abnormalities, irrespective of cardiac hypertrophy, in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2000, 102:1346-1350.
14. Ho C.Y., Sweitzer N.K., McDonough B., et al. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation 2002, 105:2997.
15. Nagueh S.F., McFalls J., Meyer D., et al. Tissue Doppler imaging predicts the development of hypertrophic cardiomyopathy in subjects with subclinical disease. Circulation 2003, 108:395-398.
16. Teare D. Asymmetrical hypertrophy of the heart in young adults. Br Heart J 1958, 20:1-18.
17. Maron B.J., Roberts W.C. Quantitative analysis of cardiac muscle cell disorganization in the ventricular septum of patients with hypertrophic cardiomyopathy. Circulation 1979, 59:689-706.
18. Maron B.J., Anan T.J., Roberts W.C. Quantitative analysis of the distribution of cardiac muscle cell disorganization in the left ventricular wall of patients with hypertrophic cardiomyopathy. Circulation 1981, 63:882-894.
19. St John Sutton M.G., Lie J.T., Anderson K.R., et al. Histopathological specificity of hypertrophic obstructive cardiomyopathy. Myocardial fibre disarray and myocardial fibrosis. Br Heart J 1980, 44:433-443.
20. Tanaka M., Fujiwara H., Onodera T., et al. Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy. Br Heart J 1986, 55:575-581.
21. Factor S.M., Butany J., Sole M.J., et al. Pathologic fibrosis and matrix connective tissue in the subaortic myocardium of patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1991, 17:1343-1351.
22. Maron B.J., Epstein S.E., Roberts W.C. Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries. Am J Cardiol 1979, 43:1086-1102.
23. Maron B.J., Wolfson J.K., Epstein S.E., et al. Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol 1986, 8:545-557.
24. Marian A.J., Yu Q.T., Workman R., et al. Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet 1993, 342:1085-1086.
25. Osterop A.P., Kofflard M.J., Sandkuijl L.A., et al. At1 receptor a/c1166 polymorphism contributes to cardiac hypertrophy in subjects with hypertrophic cardiomyopathy. Hypertension 1998, 32:825-830.
26. Lechin M., Quiñones M.A., Omran A., et al. Angiotensin-I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. Circulation 1995, 92:1808-1812.
27. Klues H.G., Schiffers A., Maron B.J. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: Morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol 1995, 26:1699-1708.
28. Maron B.J., Gottdiener J.S., Epstein S.E. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two dimensional echocardiographic study of 125 patients. Am J Cardiol 1981, 48:418-428.
29. Shapiro L.M., McKenna W.J. Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: A two-dimensional echocardiographic study. J Am Coll Cardiol 1983, 2:437-444.
30. Yamaguchi H., Ishimura T., Nishiyama S., et al. Hypertrophic nonobstructive cardiomyopathy with giant negative T waves (apical hypertrophy): ventriculographic and echocardiographic features in 30 patients. Am J Cardiol 1979, 44:401-412.
31. Sakamoto T., Tei C., Murayama M., et al. Giant T wave inversion as a manifestation of asymmetrical apical hypertrophy (aah) of the left ventricle. Echocardiographic and ultrasono-cardiotomographic study. Jpn Heart J 1976, 17:611-629.
32. Webb J.G., Sasson Z., Rakowski H., et al. Apical hypertrophic cardiomyopathy: Clinical follow-up and diagnostic correlates. J Am Coll Cardiol 1990, 15:83-90.
33. Mozaffarian D., Caldwell J.H. Right ventricular involvement in hypertrophic cardiomyopathy: a case report and literature review. Clin Cardiol 2001, 24:2-8.
34. Spirito P., Bellone P., Harris K.M., et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000, 342:1778-1785.
35. Elliott P.M., Gimeno Blanes J.R., Mahon N.G., et al. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001, 357:420-424.
36. Klues H.G., Maron B.J., Dollar A.L., et al. Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy. Circulation 1992, 85:1651-1660.
37. Klues H.G., Roberts W.C., Maron B.J. Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy. Significance in producing left ventricular outflow obstruction. Circulation 1991, 84:1188-1197.
38. Kwon D.H., Smedira N.G., Thamilarasan M., et al. Characteristics and surgical outcomes of symptomatic patients with hypertrophic cardiomyopathy with abnormal papillary muscle morphology undergoing papillary muscle reorientation. J Thorac Cardiovasc Surg 2010, 140:317-324.
39. Maron B.J., Nishimura R.A., Danielson G.K. Pitfalls in clinical recognition and a novel operative approach for hypertrophic cardiomyopathy with severe outflow obstruction due to anomalous papillary muscle. Circulation 1998, 98:2505-2508.
40. Wan C.K., Dearani J.A., Sundt T.M., et al. What is the best surgical treatment for obstructive hypertrophic cardiomyopathy and degenerative mitral regurgitation?. Ann Thorac Surg 2009, 88:727-731. [Discussion 731-22].
41. Wigle E.D., Sasson Z., Henderson M.A., et al. Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Prog Cardiovasc Dis 1985, 28:1-83.
42. Nihoyannopoulos P., Karatasakis G., Frenneaux M., et al. Diastolic function in hypertrophic cardiomyopathy: relation to exercise capacity. J Am Coll Cardiol 1992, 19:536-540.
43. Bonow R.O., Vitale D.F., Maron B.J., et al. Regional left ventricular asynchrony and impaired global left ventricular filling in hypertrophic cardiomyopathy: effect of verapamil. J Am Coll Cardiol 1987, 9:1108-1116.
44. Alsaileek A.A., Valeti U., Alvarez L., et al. Diastolic dysfunction and hypertrophic cardiomyopathy is related to myocardial fibrosis as determined by cardiovascular magnetic resonance [Abstract 943-101]. J Am Coll Cardiol 2006, 47:50A.
45. Earing M.G., Ackerman M.J., O'Leary P.W. Diastolic ventricular dysfunction as a marker for hypertrophic cardiomyopathy in a family with a novel alpha-tropomyosin mutation. J Am Soc Echocardiogr 2003, 16:698-702.
46. Menon S.C., Eidem B.W., Dearani J.A., et al. Diastolic dysfunction and its histopathological correlation in obstructive hypertrophic cardiomyopathy in children and adolescents. J Am Soc Echocardiogr 2009, 22:1327-1334.
47. Spirito P., Maron B.J., Chiarella F., et al. Diastolic abnormalities in patients with hypertrophic cardiomyopathy: Relation to magnitude of left ventricular hypertrophy. Circulation 1985, 72:310-316.
48. Wigle E.D., Wilansky S. Diastolic dysfunction in hypertrophic cardiomyopathy. Heart Fail 1987, 3:82-93.
49. Geske J.B., Sorajja P., Nishimura R.A., et al. Evaluation of left ventricular filling pressures by Doppler echocardiography in patients with hypertrophic cardiomyopathy: Correlation with direct left atrial pressure measurement at cardiac catheterization. Circulation 2007, 116:2702-2708.
50. Geske J.B., Sorajja P., Nishimura R.A., et al. The relationship of left atrial volume and left atrial pressure in patients with hypertrophic cardiomyopathy: an echocardiographic and cardiac catheterization study. J Am Soc Echocardiogr 2009, 22:961-966.
51. Kjaergaard J., Johnson B.D., Pellikka P.A., et al. Left atrial index is a predictor of exercise capacity in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2005, 18:1373-1380.
52. Cannon R.O., Rosing D.R., Maron B.J., et al. Myocardial ischemia in patients with hypertrophic cardiomyopathy: Contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures. Circulation 1985, 71:234-243.
53. Cannon R.O., Schenke W.H., Maron B.J., et al. Differences in coronary flow and myocardial metabolism at rest and during pacing between patients with obstructive and patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 1987, 10:53-62.
54. Tanaka M., Fujiwara H., Onodera T., et al. Quantitative analysis of narrowings of intramyocardial small arteries in normal hearts, hypertensive hearts, and hearts with hypertrophic cardiomyopathy. Circulation 1987, 75:1130-1139.
55. Maron M.S., Olivotto I., Zenovich A.G., et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 2006, 114:2232-2239.
56. Wigle E.D., Rakowski H., Kimball B.P., et al. Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation 1995, 92:1680-1692.
57. Jiang L., Levine R.A., King M.E., et al. An integrated mechanism for systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy based on echocardiographic observations. Am Heart J 1987, 113:633-644.
58. Shah P.M., Taylor R.D., Wong M. Abnormal mitral valve coaptation in hypertrophic obstructive cardiomyopathy: Proposed role in systolic anterior motion of mitral valve. Am J Cardiol 1981, 48:258-262.
59. Sherrid M.V. Dynamic left ventricular outflow obstruction in hypertrophic cardiomyopathy revisited: Significance, pathogenesis, and treatment. Cardiol Rev 1998, 6:135-145.
60. Sherrid M.V., Chu C.K., Delia E., et al. An echocardiographic study of the fluid mechanics of obstruction in hypertrophic cardiomyopathy. J Am Coll Cardiol 1993, 22:816-825.
61. Sherrid M.V., Gunsburg D.Z., Moldenhauer S., et al. Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2000, 36:1344-1354.
62. Frenneaux M.P., Counihan P.J., Caforio A.L., et al. Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. Circulation 1990, 82:1995-2002.
63. Sadoul N., Prasad K., Elliott P.M., et al. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 1997, 96:2987-2991.
64. Olivotto I., Maron B.J., Montereggi A., et al. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999, 33:2044-2051.
65. Elliott P.M., Poloniecki J., Dickie S., et al. Sudden death in hypertrophic cardiomyopathy: Identification of high risk patients. J Am Coll Cardiol 2000, 36:2212-2218.
66. Maki S., Ikeda H., Muro A., et al. Predictors of sudden cardiac death in hypertrophic cardiomyopathy. Am J Cardiol 1998, 82:774-778.
67. McKenna W.J., Franklin R.C., Nihoyannopoulos P., et al. Arrhythmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol 1988, 11:147-153.
68. Shah P.M., Adelman A.G., Wigle E.D., et al. The natural (and unnatural) history of hypertrophic obstructive cardiomyopathy. Circ Res 1974, 35:179-195.
69. McKenna W., Deanfield J., Faruqui A., et al. Prognosis in hypertrophic cardiomyopathy: Role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol 1981, 47:532-538.
70. Fay W.P., Taliercio C.P., Ilstrup D.M., et al. Natural history of hypertrophic cardiomyopathy in the elderly. J Am Coll Cardiol 1990, 16:821-826.
71. Maron B.J., Spirito P. Impact of patient selection biases on the perception of hypertrophic cardiomyopathy and its natural history. Am J Cardiol 1993, 72:970-972.
72. Cecchi F., Olivotto I., Montereggi A., et al. Hypertrophic cardiomyopathy in Tuscany: Clinical course and outcome in an unselected regional population. J Am Coll Cardiol 1995, 26:1529-1536.
73. Maron B.J., Casey S.A., Poliac L.C., et al. Clinical course of hypertrophic cardiomyopathy in a regional united states cohort. JAMA 1999, 281:650-655.
74. Cannan C.R., Reeder G.S., Bailey K.R., et al. Natural history of hypertrophic cardiomyopathy. A population-based study, 1976 through 1990. Circulation 1995, 92:2488-2495.
75. Maron B.J., Olivotto I., Spirito P., et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 2000, 102:858-864.
76. Elliott P., Spirito P. Prevention of hypertrophic cardiomyopathy-related deaths: Theory and practice. Heart 2008, 94:1269-1275.
77. Maron B.J., Chaitman B.R., Ackerman M.J., et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 2004, 109:2807-2816. Working Groups of the American Heart Association Committee on Exercise CR.
78. Maron B.J., Epstein S.E., Roberts W.C. Causes of sudden death in competitive athletes. J Am Coll Cardiol 1986, 7:204-214.
79. Maron B.J., Shirani J., Poliac L.C., et al. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA 1996, 276:199-204.
80. Elliott P.M., Sharma S., Varnava A., et al. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999, 33:1596-1601.
81. Cecchi F., Montereggi A., Olivotto I., et al. Risk for atrial fibrillation in patients with hypertrophic cardiomyopathy assessed by signal averaged P wave duration. Heart 1997, 78:44-49.
82. Olivotto I., Cecchi F., Casey S.A., et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001, 104:2517-2524.
83. Robinson K., Frenneaux M.P., Stockins B., et al. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol 1990, 15:1279-1285.
84. Maron B.J., Olivotto I., Bellone P., et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002, 39:301-307.
85. Spirito P., Rapezzi C., Bellone P., et al. Infective endocarditis in hypertrophic cardiomyopathy: Prevalence, incidence, and indications for antibiotic prophylaxis. Circulation 1999, 99:2132-2137.
86. Spirito P., Maron B.J., Bonow R.O., et al. Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. Am J Cardiol 1987, 60:123-129.
87. Biagini E., Coccolo F., Ferlito M., et al. Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients. J Am Coll Cardiol 2005, 46:1543-1550.
88. Ommen S.R. There is much more to the recipe than just outflow obstruction. J Am Coll Cardiol 2005, 46:1551-1552.
89. McLeod C.J., Ackerman M.J., Nishimura R.A., et al. Outcome of patients with hypertrophic cardiomyopathy and a normal electrocardiogram. J Am Coll Cardiol 2009, 54:229-233.
90. Ingham R.E., Mason J.W., Rossen R.M., et al. Electrophysiologic findings in patients with idiopathic hypertrophic subaortic stenosis. Am J Cardiol 1978, 41:811-816.
91. McKenna W.J., Chetty S., Oakley C.M., et al. Arrhythmia in hypertrophic cardiomyopathy: Exercise and 48 hour ambulatory electrocardiographic assessment with and without beta adrenergic blocking therapy. Am J Cardiol 1980, 45:1-5.
92. McKenna W.J., England D., Doi Y.L., et al. Arrhythmia in hypertrophic cardiomyopathy. I: Influence on prognosis. Br Heart J 1981, 46:168-172.
93. Lever H.M., Karam R.F., Currie P.J., et al. Hypertrophic cardiomyopathy in the elderly. Distinctions from the young based on cardiac shape. Circulation 1989, 79:580-589.
94. Binder J., Ommen S.R., Gersh B.J., et al. Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: Septal morphological features predict the presence of myofilament mutations. Mayo Clin Proc 2006, 81:459-467.
95. Maron B.J., Niimura H., Casey S.A., et al. Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. J Am Coll Cardiol 2001, 38:315-321.
96. Charron P., Dubourg O., Desnos M., et al. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. Circulation 1998, 97:2230-2236.
97. Niimura H., Bachinski L.L., Sangwatanaroj S., et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 1998, 338:1248-1257.
98. Nagueh S., Bachinski L., Meyer D., et al. Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis prior to and independent of hypertrophy. Circulation 2001, 104:128-130.
99. Alboliras E.T., Shub C., Gomez M.R., et al. Spectrum of cardiac involvement in Friedreich's ataxia: Clinical, electrocardiographic and echocardiographic observations. Am J Cardiol 1986, 58:518-524.
100. Chandrasekaran K., Aylward P.E., Fleagle S.R., et al. Feasibility of identifying amyloid and hypertrophic cardiomyopathy with the use of computerized quantitative texture analysis of clinical echocardiographic data. J Am Coll Cardiol 1989, 13:832-840.
101. Ommen S.R., Nishimura R.A., Edwards W.D. Fabry disease: A mimic for obstructive hypertrophic cardiomyopathy?. Heart 2003, 89:929-930.
102. Sachdev B., Takenaka T., Teraguchi H., et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002, 105:1407-1411.
103. Pelliccia A., Maron B.J., De Luca R., et al. Remodeling of left ventricular hypertrophy in elite athletes after long-term deconditioning. Circulation 2002, 105:944-949.
104. Pelliccia A., Maron B.J., Spataro A., et al. The upper limit of physiologic cardiac hypertrophy in highly trained elite athletes. N Engl J Med 1991, 324:295-301.
105. Sharma S., Maron B.J., Whyte G., et al. Physiologic limits of left ventricular hypertrophy in elite junior athletes: Relevance to differential diagnosis of athlete's heart and hypertrophic cardiomyopathy. J Am Coll Cardiol 2002, 40:1431-1436.
106. Whyte G.P., George K., Sharma S., et al. The upper limit of physiological cardiac hypertrophy in elite male and female athletes: the British experience. Eur J Appl Physiol 2004, 92:592-597.
107. Galanti G., Toncelli L., Del Furia F., et al. Tissue Doppler imaging can be useful to distinguish pathological from physiological left ventricular hypertrophy: A study in master athletes and mild hypertensive subjects. Cardiovasc Ultrasound 2009, 7:48.
108. Indermühle A., Vogel R., Meier P., et al. The relative myocardial blood volume differentiates between hypertensive heart disease and athlete's heart in humans. Eur Heart J 2006, 27:1571-1578.
109. Maron B.J. Distinguishing hypertrophic cardiomyopathy from athlete's heart: A clinical problem of increasing magnitude and significance. Heart 2005, 91:1380-1382.
110. Palka P., Lange A., Fleming A.D., et al. Differences in myocardial velocity gradient measured throughout the cardiac cycle in patients with hypertrophic cardiomyopathy, athletes and patients with left ventricular hypertrophy due to hypertension. J Am Coll Cardiol 1997, 30:760-768.
111. Klues H.G., Roberts W.C., Maron B.J. Morphological determinants of echocardiographic patterns of mitral valve systolic anterior motion in obstructive hypertrophic cardiomyopathy. Circulation 1993, 87:1570-1579.
112. Schwammenthal E., Block M., Schwartzkopff B., et al. Prediction of the site and severity of obstruction in hypertrophic cardiomyopathy by color flow mapping and continuous wave Doppler echocardiography. J Am Coll Cardiol 1992, 20:964-972.
113. Ommen S.R., Shah P.M., Tajik A.J. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: Past, present and future. Heart 2008, 94:1276-1281.
114. Falicov R.E., Resnekov L., Bharati S., et al. Mid-ventricular obstruction: A variant of obstructive cardiomyopathy. Am J Cardiol 1976, 37:432-437.
115. Martinez M.W., Sorajja P., Ommen S.R. Mid-cavitary obstruction in hypertrophic cardiomyopathy. Heart 2008, 94:1287.
116. Bruce C.J., Nishimura R.A., Tajik A.J., et al. Fixed left ventricular outflow tract obstruction in presumed hypertrophic obstructive cardiomyopathy: Implications for therapy. Ann Thorac Surg 1999, 68:100-104.
117. Gwathmey J.K., Warren S.E., Briggs G.M., et al. Diastolic dysfunction in hypertrophic cardiomyopathy. Effect on active force generation during systole. J Clin Invest 1991, 87:1023-1031.
118. Matsumura Y., Elliott P.M., Virdee M.S., et al. Left ventricular diastolic function assessed using Doppler tissue imaging in patients with hypertrophic cardiomyopathy: Relation to symptoms and exercise capacity. Heart 2002, 87:247-251.
119. Nishimura R.A., Tajik A.J. Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician's Rosetta stone. J Am Coll Cardiol 1997, 30:8-18.
120. Desai M.Y., Ommen S.R., McKenna W.J., et al. Imaging phenotype versus genotype in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging 2011, 4:156-168.
121. Maron M.S. The current and emerging role of cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy. J Cardiovasc Transl Res 2009, 2:415-425.
122. Harrigan C.J., Appelbaum E., Maron B.J., et al. Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol 2008, 101:668-673.
123. Maron B.J., Haas T.S., Lesser J.R. Images in cardiovascular medicine. Diagnostic utility of cardiac magnetic resonance imaging in monozygotic twins with hypertrophic cardiomyopathy and identical pattern of left ventricular hypertrophy. Circulation 2007, 115:e627-e628.
124. Maron M.S., Maron B.J., Harrigan C., et al. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol 2009, 54:220-228.
125. Maron M.S., Finley J.J., Bos J.M., et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation 2008, 118:1541-1549.
126. Rubinshtein R., Glockner J.F., Ommen S.R., et al. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail 2010, 3:51-58.
127. Adabag A.S., Maron B.J., Appelbaum E., et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 2008, 51:1369-1374.
128. O'Hanlon R., Grasso A., Roughton M., et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 2010, 56:867-874.
129. Bruder O., Wagner A., Jensen C.J., et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2010, 56:875-887.
130. Moon J.C., McKenna W.J., McCrohon J.A., et al. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003, 41:1561-1567.
131. Binder J., Attenhofer Jost C.H., Klarich K.W., et al. Apical hypertrophic cardiomyopathy: Prevalence and correlates of apical outpouching. J Am Soc Echocardiogr 2011, [epub ahead of print].
132. Gersh B.J., Maron B.J., Bonow R.O., et al. ACCF/AHA guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy. J Am Coll Cardiol 2011, [in press].
133. Maron B.J., Seidman J.G., Seidman C.E. Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy. J Am Coll Cardiol 2004, 44:2125-2132.
134. Lim D.S., Lutucuta S., Bachireddy P., et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 2001, 103:789-791.
135. Patel R., Nagueh S.F., Tsybouleva N., et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001, 104:317-324.
136. Adelman A.G., Shah P.M., Gramiak R., et al. Long-term propranolol therapy in muscular subaortic stenosis. Br Heart J 1970, 32:804-811.
137. Flamm M.D., Harrison D.C., Hancock E.W. Muscular subaortic stenosis. Prevention of outflow obstruction with propranolol. Circulation 1968, 38:846-858.
138. Bonow R.O., Dilsizian V., Rosing D.R., et al. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: Short- and long-term effects. Circulation 1985, 72:853-864.
139. Rosing D.R., Condit J.R., Maron B.J., et al. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: III. Effects of long-term administration. Am J Cardiol 1981, 48:545-553.
140. Rosing D.R., Kent K.M., Borer J.S., et al. Verapamil therapy: A new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects. Circulation 1979, 60:1201-1207.
141. Rosing D.R., Kent K.M., Maron B.J., et al. Verapamil therapy: A new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status. Circulation 1979, 60:1208-1213.
142. Epstein S.E., Rosing D.R. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation 1981, 64:437-441.
143. Sherrid M.V., Barac I., McKenna W.J., et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005, 45:1251-1258.
144. Pollick C., Detsky A., Ogilvie R.I., et al. Disopyramide versus propranolol in hypertrophic cardiomyopathy: Double-blind randomized trial. Circulation 1985, 72:155.
145. Pollick C., Kimball B., Henderson M., et al. Disopyramide in hypertrophic cardiomyopathy. I. Hemodynamic assessment after intravenous administration. Am J Cardiol 1988, 62:1248-1251.
146. Sherrid M., Delia E., Dwyer E. Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy. Am J Cardiol 1988, 62:1085-1088.
147. Morrow A.G. Hypertrophic subaortic stenosis. Operative methods utilized to relieve left ventricular outflow obstruction. J Thorac Cardiovasc Surg 1978, 76:423-430.
148. Morrow A.G., Lambrew C.T., Braunwald E. Idiopathic hypertrophic subaortic stenosis. II. Operative treatment and the results of pre- and postoperative hemodynamic evaluations. Circulation 1964, 30(suppl 4):120-151.
149. Morrow A.G., Reitz B.A., Epstein S.E., et al. Operative treatment in hypertrophic subaortic stenosis. Techniques, and the results of pre and postoperative assessments in 83 patients. Circulation 1975, 52:88-102.
150. Williams W.G., Wigle E.D., Rakowski H., et al. Results of surgery for hypertrophic obstructive cardiomyopathy. Circulation 1987, 76:V104-V108.
151. McCully R.B., Nishimura R.A., Tajik A.J., et al. Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy. Circulation 1996, 94:467-471.
152. Schönbeck M.H., Brunner-La Rocca H.P., Vogt P.R., et al. Long-term follow-up in hypertrophic obstructive cardiomyopathy after septal myectomy. Ann Thorac Surg 1998, 65:1207-1214.
153. Schulte H.D., Borisov K., Gams E., et al. Management of symptomatic hypertrophic obstructive cardiomyopathy-long-term results after surgical therapy. J Thorac Cardiovasc Surg 1999, 47:213-218.
154. Woo A., Williams W.G., Choi R., et al. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation 2005, 111:2033-2041.
155. Ommen S.R., Maron B.J., Olivotto I., et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005, 46:470-476.
156. Smedira N.G., Lytle B.W., Lever H.M., et al. Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy. Ann Thorac Surg 2008, 85:127-133.
157. McLeod C.J., Ommen S.R., Ackerman M.J., et al. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. Eur Heart J 2007, 28:2583-2588.
158. Krajcer Z., Leachman R.D., Cooley D.A., et al. Septal myotomy-myomectomy versus mitral valve replacement in hypertrophic cardiomyopathy. Ten-year follow-up in 185 patients. Circulation 1989, 80:157-164.
159. Yu E.H., Omran A.S., Wigle E.D., et al. Mitral regurgitation in hypertrophic obstructive cardiomyopathy: Relationship to obstruction and relief with myectomy. J Am Coll Cardiol 2000, 36:2219-2225.
160. Schoendube F.A., Klues H.G., Reith S., et al. Surgical correction of hypertrophic obstructive cardiomyopathy with combined myectomy, mobilisation and partial excision of the papillary muscles. Eur J Cardiothorac Surg 1994, 8:603-608.
161. Grigg L.E., Wigle E.D., Williams W.G., et al. Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: Clarification of pathophysiology and importance in intraoperative decision making. J Am Coll Cardiol 1992, 20:42-52.
162. Marwick T.H., Stewart W.J., Lever H.M., et al. Benefits of intraoperative echocardiography in the surgical management of hypertrophic cardiomyopathy. J Am Coll Cardiol 1992, 20:1066-1072.
163. Ommen S.R., Park S.H., Click R.L., et al. Impact of intraoperative transesophageal echocardiography in the surgical management of hypertrophic cardiomyopathy. Am J Cardiol 2002, 90:1022-1024.
164. Faber L., Meissner A., Ziemssen P., et al. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients. Heart 2000, 83:326-331.
165. Faber L., Seggewiss H., Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Results with respect to intraprocedural myocardial contrast echocardiography. Circulation 1998, 98:2415-2421.
166. Lakkis N.M., Nagueh S.F., Kleiman N.S., et al. Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 1998, 98:1750-1755.
167. Nagueh S.F., Lakkis N.M., He Z.X., et al. Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1998, 32:225-229.
168. Fernandes V.L., Nielsen C., Nagueh S.F., et al. Follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy the Baylor and Medical University of South Carolina experience 1996 to 2007. JACC Cardiovasc Interv 2008, 1:561-570.
169. Sorajja P., Valeti U., Nishimura R.A., et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation 2008, 118:131-139.
170. Knight C., Kurbaan A.S., Seggewiss H., et al. Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: Outcome in the first series of patients. Circulation 1997, 95:2075-2081.
171. Faber L., Seggewiss H., Ziemssen P., et al. Intraprocedural myocardial contrast echocardiography as a routine procedure in percutaneous transluminal septal myocardial ablation: Detection of threatening myocardial necrosis distant from the septal target area. Catheter Cardiovasc Interv 1999, 47:462-466.
172. Faber L., Ziemssen P., Seggewiss H. Targeting percutaneous transluminal septal ablation for hypertrophic obstructive cardiomyopathy by intraprocedural echocardiographic monitoring. J Am Soc Echocardiogr 2000, 13:1074-1079.
173. Gietzen F.H., Leuner C.J., Obergassel L., et al. Role of transcoronary ablation of septal hypertrophy in patients with hypertrophic cardiomyopathy, New York Heart Association functional class III or IV, and outflow obstruction only under provocable conditions. Circulation 2002, 106:454-459.
174. Gietzen F.H., Leuner C.J., Raute-Kreinsen U., et al. Acute and long-term results after transcoronary ablation of septal hypertrophy (Tash). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 1999, 20:1342-1354.
175. Knight C.J. Five years of percutaneous transluminal septal myocardial ablation. Heart 2000, 83:255-256.
176. Kuhn H., Gietzen F., Leuner C. The abrupt no-flow. Eur Heart J 2002, 23:91-93.
177. Lakkis N.M., Nagueh S.F., Dunn J.K., et al. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up. J Am Coll Cardiol 2000, 36:852-855.
178. ten Cate F.J., Soliman O.I., Michels M., et al. Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: A word of caution. Circ Heart Fail 2010, 3:362-369.
179. Firoozi S., Elliott P.M., Sharma S., et al. Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy. A comparison of clinical, haemodynamic and exercise outcomes. Eur Heart J 2002, 23:1617-1624.
180. Nagueh S.F., Ommen S.R., Lakkis N.M., et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001, 38:1701-1706.
181. Leonardi R.A., Kransdorf E.P., Simel D.L., et al. Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy: Comparative rates of overall mortality and sudden cardiac death after treatment. Circ Cardiovasc Interv 2010, 3:97-104.
182. Alam M., Dokainish H., Lakkis N.M. Hypertrophic obstructive cardiomyopathy-alcohol septal ablation vs. Myectomy: A meta-analysis. Eur Heart J 2009, 30:1080-1087.
183. Cuoco F.A., Spencer W.H., Fernandes V.L., et al. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. J Am Coll Cardiol 2008, 52:1718-1723.
184. Noseworthy P.A., Rosenberg M.A., Fifer M.A., et al. Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol 2009, 104:128-132.
185. Maron B.J., Spirito P., Shen W.K., et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007, 298:405-412.
186. Sorajja P., Binder J., Ommen S.R., et al. Predictors of surgical-like results with alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation 2009, 120(suppl 2):S929.
187. Fifer M.A. Controversies in cardiovascular medicine. Most fully informed patients choose septal ablation over septal myectomy. Circulation 2007, 116:207-216. [Discussion 216].
188. Maron B.J. Controversies in cardiovascular medicine. Surgical myectomy remains the primary treatment option for severely symptomatic patients with obstructive hypertrophic cardiomyopathy. Circulation 2007, 116:196-206. [Discussion 206].
189. Fananapazir L., Cannon R.O., Tripodi D., et al. Impact of dual-chamber permanent pacing in patients with obstructive hypertrophic cardiomyopathy with symptoms refractory to verapamil and beta-adrenergic blocker therapy. Circulation 1992, 85:2149-2161.
190. Fananapazir L., Epstein N.D., Curiel R.V., et al. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation 1994, 90:2731-2742.
191. Gadler F., Linde C., Juhlin-Dannfelt A., et al. Long-term effects of dual chamber pacing in patients with hypertrophic cardiomyopathy without outflow tract obstruction at rest. Eur Heart J 1997, 18:636-642.
192. Kappenberger L., Linde C., Daubert C., et al. Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. Pic study group. Eur Heart J 1997, 18:1249-1256.
193. Kappenberger L.J., Linde C., Jeanrenaud X., et al. Clinical progress after randomized on/off pacemaker treatment for hypertrophic obstructive cardiomyopathy. Pacing in Cardiomyopathy (PIC) Study Group. Europace 1999, 1:77-84.
194. Linde C., Gadler F., Kappenberger L., et al. Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. PIC study group. Pacing in Cardiomyopathy. Am J Cardiol 1999, 83:903-907.
195. Maron B.J., Nishimura R.A., McKenna W.J., et al. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (m-pathy). Circulation 1999, 99:2927-2933.
196. Nishimura R.A., Trusty J.M., Hayes D.L., et al. Dual-chamber pacing for hypertrophic cardiomyopathy: A randomized, double-blind, crossover trial. J Am Coll Cardiol 1997, 29:435-441.
197. Ommen S.R., Nishimura R.A., Squires R.W., et al. Comparison of dual-chamber pacing versus septal myectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy: a comparison of objective hemodynamic and exercise end points. J Am Coll Cardiol 1999, 34:191-196.
198. Erwin J.P., Nishimura R.A., Lloyd M.A., et al. Dual chamber pacing for patients with hypertrophic obstructive cardiomyopathy: A clinical perspective in 2000. Mayo Clin Proc 2000, 75:173-180.
199. Binder J., Ommen S.R., Sorajja P., et al. Clinical and echocardiographic variables fail to predict response to dual-chamber pacing for hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2008, 21:796-800.
200. Elliott P.M., Gimeno J.R., Tomé M.T., et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 2006, 27:1933-1941.
201. Ommen S.R., Gersh B.J. Sudden cardiac death risk in hypertrophic cardiomyopathy. Eur Heart J 2009, 30:2558-2559.
202. Sorajja P., Ommen S., Nishimura R., et al. Myocardial bridging in adult patients with hypertrophic cardiomyopathy (abstract p2904). Eur Heart J 2003, 24:558.
203. Fananapazir L., Chang A.C., Epstein S.E., et al. Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, holter, hemodynamic, and electrophysiological findings. Circulation 1992, 86:730-740.
204. Fananapazir L., Tracy C.M., Leon M.B., et al. Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy. A consecutive analysis in 155 patients. Circulation 1989, 80:1259-1268.
205. Bos J.M., Maron B.J., Ackerman M.J., et al. Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy. Am J Cardiol 2010, 106:1481-1486.
206. Lin G., Nishimura R.A., Gersh B.J., et al. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy. Heart 2009, 95:709-714.